In what could open the door to a potential cure for multiple 
myeloma, Swedish scientists have discovered that a single antibody — a 
protein used by the immune system to fight infection and disease — could
 be the key to treating the cancer of the blood, which now has no 
effective long-term treatment.
 
Researchers at Lund University in Sweden tested thousands of 
antibodies to identify one in particular — known as BI-505 — that they 
said was shown to have “a powerful effect on the tumor cells in both 
cell studies and animal experiments.” Preliminary tests of BI-505 on 
seriously ill patients also found it to be safe, and another study of 
its treatment effects on newly diagnosed individuals has just begun. 
 
“We tested the antibody in various ways, including on tumor cells 
from myeloma patients that have been transplanted into mice,” said Lund 
researcher Markus Hansson. “The tests showed that the antibody is able 
to destroy myeloma cells.”
 
Special: This Small Group of Doctors is Quietly Curing Cancer
Myeloma develops when cells in the bone marrow become cancerous, 
disrupting blood formation and resulting in fatigue, weakened bones, and
 life-threatening  kidney failure. Several drugs are currently used to 
treat multiple myeloma, but none eradicate the disease. There is no 
cure. Fewer than half of all patients diagnosed with the condition live 
longer than five years.
 
Drugs based on antibodies, which are a part of the immune system 
and fight off foreign bodies, are a promising new line of medical 
research and are now used to treat some inflammatory diseases and types 
of cancer.
 
The new Lund study will involve 15 patients and is expected to be 
completed this year. If the results are promising, Hansson and his 
colleagues will test BI-505 in larger studies designed to uncover the 
best way of using the new antibody — alone or in combination with other 
drugs.
 
No comments:
Post a Comment